Clinical Obstetrics and Gynecology

Independence Blue Cross Awards 2022 Clinical Care Innovation Grants to Jefferson Health, Temple Health, Penn Medicine, and Trinity Health Mid-Atlantic

Retrieved on: 
Friday, July 8, 2022

PHILADELPHIA, July 8, 2022 /PRNewswire/ -- Independence Blue Cross (Independence) announced today that it has awarded six Clinical Care Innovation Grants (CCI Grants) to local health systems to support projects aimed at improving the quality and delivery of health care.

Key Points: 
  • PHILADELPHIA, July 8, 2022 /PRNewswire/ -- Independence Blue Cross (Independence) announced today that it has awarded six Clinical Care Innovation Grants (CCI Grants) to local health systems to support projects aimed at improving the quality and delivery of health care.
  • The health systems receiving grants include Jefferson Health, Temple Health, Penn Medicine, and Trinity Health Mid-Atlantic.
  • "Supporting these grants is just one way that we work collaboratively with our excellent network of health care providers.
  • Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Retrieved on: 
Monday, September 27, 2021

As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.

Key Points: 
  • As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.
  • "We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind.
  • "I'm very excited to lead our team and launch a clinical studyfor the treatment of female Hypoactive Sexual Desire Disorder," said Dr. Joel Raskin, Chief Medical Officer, MINDCURE.
  • This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder."

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

Retrieved on: 
Thursday, September 9, 2021

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD).

Key Points: 
  • TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD).
  • Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecules.
  • Major depressive disorder (MDD), treatment-resistant depression (TRD) and postpartum depression (PPD) share similar etiologies and negatively impact functioning.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.